Clinical development of RTS,S/AS malaria vaccine: A systematic review of clinical Phase I-III trials

Future Microbiology

Volumn 10, Issue 10, 2015, Pages 1553-1578

  Agnandji, Selidji T ^a,b   Fernandes, José F ^a,b   Bache, Emmanuel B ^a,b   Ramharter, Michael ^a,b,c  

^a Hôpital Albert Schweitzer   (Gabon)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

anti CSP; anti HBs; AS01; AS02; geometric mean concentration; immune responses; RTS,S AS; vaccine efficacy

Indexed keywords

GAMMA INTERFERON; HEPATITIS B VACCINE; INTERLEUKIN 2; MALARIA VACCINE;

ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DIAPER DERMATITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE CONVULSION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MALARIA; MALARIA CONTROL; MEMORY T LYMPHOCYTE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; T LYMPHOCYTE; VACCINATION; ADULT; AFRICA SOUTH OF THE SAHARA; CHILD; IMMUNOLOGY; INFANT; MALARIA, FALCIPARUM; MORTALITY; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD;

ADULT; AFRICA SOUTH OF THE SAHARA; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; VACCINATION;

EID: 84945264118     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.90     Document Type: Article

References (70)

1. World Health Organization. World Malaria Report 2011 (2011). http://www.who.int
2. World Health Organization. World Malaria Report 2010 (2010). http://www.who.int
3. World Health Organization. World Malaria Report 2012 (2012). http://www.who.int
4. World Health Organization. World malaria report 2013 (2013). http://www.who.int
5. World Health Organization. World Malaria Report 2014 (2014). http://apps.who.int
6. World Health Organization. Tables of malaria vaccine projects globally (2015). http://www.who.int
7. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum. Vaccin. 6(1), 90-96 (2010
8. Doud MB, Koksal AC, Mi L-Z, Song G, Lu C, Springer TA. Unexpected fold in the circumsporozoite protein target of malaria vaccines. Proc. Natl Acad. Sci. USA 109(20), 7817-7822 (2012
9. Gordon DM, McGovern TW, Krzych U et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171(6), 1576-1585 (1995
10. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 33(4), 492-503 (2010
11. Kester KE, McKinney DA, Tornieporth N et al. A Phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine 25(29), 5359-5366 (2007
12. Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336(2), 86-91 (1997)
13. Kester KE, McKinney DA, Tornieporth N et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183(4), 640-647 (2001
14. Schwenk R, Asher L V, Chalom I et al. Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine. Parasite Immunol. 25 (1), 17-25 (2003
15. Lalvani A, Moris P, Voss G et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/ SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J. Infect. Dis. 180(5), 1656-1664 (1999
16. Doherty JF, Pinder M, Tornieporth N et al. A Phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Am. J. Trop. Med. Hyg. 61(6), 865-868 (1999
17. Bojang KA, Milligan PJM, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358(9297), 1927-1934 (2001
18. Alloueche ALI, Milligan P, Conway DJ et al. Protective efficacy of the rts,s/as02 Plasmodium falciparum malaria vaccine is not strain specific. Am. J. Trop. Med. Hyg. 68(1), 97-101 (2003
19. Stoute JA, Heppner DG, Mason CJ et al. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya. Am. J. Trop. Med. Hyg. 75(1), 166-170 (2006
20. Bojang KA, Olodude F, Pinder M et al. Safety and immunogenicty of RTS,S/ AS02A candidate malaria vaccine in Gambian children. Vaccine 23(32), 4148-4157 (2005
21. Macete E, Aponte JJ, Guinovart C et al. Safety and immunogenicity of the RTS,S/ AS02A candidate malaria vaccine in children aged 1-4 in Mozambique. Trop. Med. Int. Heal. 12(1), 37-46 (2007
22. Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364(9443), 1411-1420 (2004)
23. Aide P, Dobaño C, Sacarlal J et al. Four year immunogenicity of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine 29(35), 6059-6067 (2011
24. Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366(9502), 2012-2018 (2005
25. Sacarlal J, Aide P, Aponte JJ et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis. 200(3), 329-336 (2009
26. Kester KE, Cummings JF, Ofori-Anyinam O et al. Randomized, double-blind, Phase 2a trial of falciparum malaria vaccines RTS,S/ AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200(3), 337-346 (2009
27. Lumsden JM, Schwenk RJ, Rein LE et al. Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-? producing effector and central memory CD4 (+) T cells. PLoS ONE 6(7), e20775 (2011
28. Macete E V, Sacarlal J, Aponte JJ et al. Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial. Trials 8, 11 (2007
29. Aponte JJ, Aide P, Renom M et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled Phase I/IIb trial. Lancet 370(9598), 1543-1551 (2007
30. Polhemus ME, Remich SA, Ogutu BR et al. Evaluation of RTS,S/AS02A and RTS,S/ AS01B in adults in a high malaria transmission area. PLoS ONE 4(7) (2009
31. Waitumbi JN, Anyona SB, Hunja CW et al. Impact of RTS,S/AS02 (A) and RTS,S/AS01 (B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS ONE 4(11), e7849 (2009
32. Abdulla S, Oberholzer R, Juma O et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N. Engl. J. Med. 359 (24), 2533-2544 (2008
33. Lell B, Agnandji S, von Glasenapp I et al. A Randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS ONE 4(10), e7611 (2009
34. Agnandji ST, Fendel R, Mestré M et al. Induction of Plasmodium falciparum-specific CD4 (+) T cells and memory B cells in Gabonese children vaccinated with RTS,S/ AS01 (E) and RTS,S/AS02 (D). PLoS ONE 6(4), e18559 (2011
35. Owusu-Agyei S, Ansong D, Asante K et al. Randomized controlled trial of RTS,S/AS02 (D) and RTS,S/AS01 (E) Malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE 4(10), e7302 (2009
36. Ansong D, Asante KP, Vekemans J et al. T-cell responses to the RTS,S/AS01 (E) and RTS,S/AS02 (D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS ONE 6(4), e18891 (2011
37. Bejon P, Lusingu J, Olotu A et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359(24), 2521-2532 (2008
38. Olotu A, Lusingu J, Leach A et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect. Dis. 11(2), 102-109 (2011
39. Agnandji ST, Asante KP, Lyimo J et al. Evaluation of the safety and immunogenicity of the RTS, S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J. Infect. Dis. 202(7), 1076-1087 (2010
40. Asante KP, Abdulla S, Agnandji S et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expandedprogramme- on-immunisation vaccines: 19 month follow-up of a randomised, open-label, Phase II trial. Lancet Infect. Dis. 11(10), 741-749 (2011
41. Leroux-Roels G, Leroux-Roels I, Clement F et al. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines. Hum. Vaccin. Immunother. 10(8), 2211-2219 (2014
42. The Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a Phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 11(7), e1001685 (2014
43. Bojang K, Milligan P, Pinder M et al. Five year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. Hum. Vaccin. 5 (4), 242-247 (2009
44. Stoute JA, Kester KE, Krzych U et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178 (4), 1139-1144 (1998
45. Asante KP, Abdulla S, Agnandji ST et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, Phase II trial. Lancet Infect. Dis. 11(10), 741-749 (2011
46. Olotu A, Clement F, Jongert E et al. Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children. PLoS ONE 9(12), e115126 (2014
47. Ajua A, Lell B, Agnandji ST et al. The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01 (E) on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants. Malar. J. 14, 72 (2015
48. Aide P, Aponte JJ, Renom M et al. Safety, immunogenicity and duration of protection of the RTS,S/AS02 (D) malaria vaccine: one year follow-up of a randomized controlled Phase I/IIb trial. PLoS ONE 5(11), e13838 (2010
49. Abdulla S, Salim N, Machera F et al. Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02 (D) malaria vaccine in infants living in a malaria-endemic region. Malar. J. 12, 11 (2013
50. White MT, Bejon P, Olotu A et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from Phase II trials of the RTS,S malaria vaccine. BMC Med. 12, 117 (2014
51. Pinder M, Reece WHH, Plebanski M et al. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in the Gambia. Clin. Exp. Immunol. 135(2), 286-293 (2004
52. Olotu A, Moris P, Mwacharo J et al. Circumsporozoite-specific T-cell responses in children vaccinated with RTS,S/AS01E and protection against P. falciparum clinical malaria. PLoS ONE 6(10), e25786 (2011
53. Barbosa A, Naniche D, Aponte JJ et al. Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique. Infect. Immun. 77(10), 4502-4509 (2009
54. Kester KE, Cummings JF, Ockenhouse CF et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 26(18), 2191-2202 (2008
55. Reece WHH, Pinder M, Gothard PK et al. A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 10(4), 406-410 (2004
56. Horowitz A, Hafalla JCR, King E et al. Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine. J. Immunol. 188(10), 5054-5062 (2012
57. Sun P, Schwenk R, White K et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-?. J. Immunol. 171(12), 6961-6967 (2003
58. Olotu AI, Fegan G, Bejon P. Further Analysis of correlates of protection from a Phase 2a trial of the falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults. J. Infect. Dis. 201(6), 970-971 (2010
59. Ndungu FM, Mwacharo J, Kimani D et al. A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/ AS01E. PLoS ONE 7(12), e52870 (2012
60. White MT, Bejon P, Olotu A et al. The relationship between RTS,S vaccine-induced antibodies, CD4+ T-cell responses and protection against Plasmodium falciparum infection. PLoS ONE 8 4), e61395 (2013
61. Olotu A, Fegan G, Wambua J et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N. Engl. J. Med. 368(12), 1111-1120 (2013
62. Guinovart C, Aponte JJ, Sacarlal J et al. Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a Phase IIb trial in Mozambican children. PLoS ONE 4(4), e5165 (2009
63. Agnandji ST, Lell B, Soulanoudjingar SS FJ. First results of Phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365(20), 1863-1875 (2011
64. The Clinical Trials Partnership; Agnandji ST, Lell B SS et al. A Phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367(24), 2284-2295 (2012
65. Bejon P, White MT, Olotu A et al. Efficacy of RTS,S malaria vaccines: individualparticipant pooled analysis of Phase II data. Lancet Infect. Dis. 13(4), 319-327 (2013
66. Enosse S, Dobaño C, Quelhas D et al. RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin. Trials 1(1), e5 (2006
67. Vahey MT, Wang Z, Kester KE et al. Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine. J. Infect. Dis. 201(4), 580-589 (2010
68. Warimwe G, Fletcher H, Olotu A et al. Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled Phase II clinical trial data. BMC Med. 11(1), 184 (2013
69. Vekemans J, Guerra Y, Lievens M et al. Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials. Hum. Vaccin. 7(12), 1309-1316 (2011
70. World Health Organization. Questions and answers on malaria vaccines (2015 http://www.who.int